Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

The liver in itai-itai disease (chronic cadmium poisoning): pathological features and metallothionein expression

Abstract

Cadmium (Cd) is a highly hepatotoxic heavy metal, which is widely dispersed in the environment. Acute Cd hepatotoxicity has been well studied in experimental animals; however, effects of prolonged exposure to Cd doses on the liver remain unclear. In the present study, to evaluate chronic Cd hepatotoxicity, we examined specimens from cases of itai-itai disease, the most severe form of chronic Cd poisoning. We compared 89 cases of itai-itai disease with 27 control cases to assess Cd concentration in organs. We also examined 80 cases of itai-itai disease and 70 control cases for histopathological evaluation. In addition, we performed immunohistochemistry for metallothionein, which binds and detoxifies Cd. Hepatic Cd concentration was higher than Cd concentration in all other organs measured in the itai-itai disease group, whereas it was second highest following renal concentration in the control group. In the liver in the itai-itai disease group, fibrosis was observed at a significantly higher rate than that in the control group. Metallothionein expression was significantly higher in the itai-itai disease group than that in the control group. Prolonged exposure to low doses of Cd leads to high hepatic accumulation, which can then cause fibrosis; however, it also causes high expression of metallothionein, which is thought to reduce Cd hepatotoxicity.

Main

Cadmium (Cd) is an environmental pollutant ranked as one of the most toxic substances,1 and human industrial activities have markedly increased its distribution in the global environment. Food is the major source of Cd exposure to the general population;2 therefore, the effects of chronic exposure to this metal are a major concern for humans. Several studies reported that even chronic exposure to low Cd doses can cause serious health effects.3, 4, 5

Itai-itai disease is the most severe form of chronic Cd poisoning caused by prolonged oral Cd ingestion. It developed in numerous inhabitants of the Jinzu River basin in Toyama Prefecture, Japan, an area most severely polluted by Cd that originated from a zinc mine located upstream. The main target organ of Cd toxicity in itai-itai disease is the kidney, where injury is manifested by tubular and glomerular dysfunction.6 Renal dysfunction causes an insufficiency of active vitamin D, followed by bone injury consisting of a combination of osteomalacia and osteoporosis. Although femoral pain and lumbago are frequently seen as the initial manifestation, the leakage of low molecular weight proteins is observed in urine test from an earlier stage. Although bone injury is secondary and treatable, renal injury is irreversible and deteriorates culminating in end-stage renal failure in severe cases.7

Although chronic Cd intoxication mainly results in renal disease, acute exposure to toxic Cd doses primarily results in liver damage.8 Acute Cd hepatotoxicity has been well studied in experimental animals, and its mechanism has been elucidated in detail.8 However, the liver of itai-itai disease patients has not been the focus in research; therefore, the effects of prolonged Cd exposure on the liver remain to be clarified. Our faculty, the University of Toyama, located in the region where itai-itai disease has occurred, maintains a large collection of autopsy specimens from itai-itai disease patients. One of the aims of the present study was to assess the histopathological characteristics of the liver of itai-itai disease cases to evaluate the effects of chronic Cd hepatotoxicity.

In previous research on heavy-metal toxicology, antitoxicity protection mechanisms have attracted a great deal of attention. Till date, several antioxidants and metal-chelating agents have been proven to be effective in protecting against Cd-induced hepatotoxicity.9, 10, 11 Among these substances, metallothionein is one of the most important substances because animal and human studies suggest that most Cd in the human body is associated with metallothionein.12 As it is reported that the induction of metallothionein following Cd exposure mainly occurs in the liver,13 the other aim of our study was to investigate metallothionein expression in order to clarify the aspect of its protective function against metal toxicity in the liver of itai-itai disease cases.

Materials and methods

Materials

We examined 89 autopsied itai-itai disease cases. All patients were elderly women. The clinical diagnosis was based on the opinion of the Ministry of Health and Welfare, with regard to itai-itai disease in Toyama Prefecture.14 The diagnosis of itai-itai disease was made when patients fulfill the following three criteria:15 (1) to live in an area polluted with Cd; (2) have symptoms that appear in adults (especially after menopause) and are not congenital, and (3) exhibit renal tubulopathy. We selected 27 non-Cd-polluted cases as the control group for comparison of Cd concentration in various organs; 70 cases with an organ other than the liver as the site of the main pathological lesion were then selected as the control group for analysis. We chose cases from a different region of Japan without risk of high Cd exposure as non-Cd-polluted cases. The demographic features of these cases are listed in Table 1.

Table 1 Demographic features of itai-itai disease (IID) and control cases

Cd Concentration

Cd concentration in organs was measured at two institutions to promise precision: (1) the Department of Pharmaceutical Science, International University of Health and Welfare and (2) the Department of Occupational and Environmental Medicine, Graduate School of Medicine and School of Medicine, Chiba University. The degree of discrepancies between the two testing methods is shown in Table 2. We adopted average Cd titers from the two institutions. As described by Kuzuhara et al,16 each tissue (fresh and unfixed, 1–10 g wet weight) was mineralized by heating in the presence of 12 N nitric acid to dryness, and the residue was taken up in 1 N nitric acid. The final preparation was subjected to instrumental analyses for Cd, with a graphite furnace atomic absorption spectrometer at 228.8 nm (Hitachi Z-8200, Hitachinaka, Japan).

Table 2 The degree of discrepancies between cadmium (Cd) measuring tests in two institutions

Pathological Analysis

Of the 89 itai-itai disease cases, we excluded 9 cases from analysis on account of their samples proving inadequate for further investigation. In addition, we excluded ischemic and/or congestive changes considered to be agonal from the evaluation, along with apparent drug-induced injuries. Fibrosis was assessed on a four-step scale: (1) perisinusoidal or periportal; (2) perisinusoidal and portal/periportal; (3) bridging fibrosis; and (4) cirrhosis. Iron accumulation was graded from 0 to 4, according to the Scheuer’s scoring system modified by Searle et al17: 0 granules absent or barely discernible at × 400; 1 granules barely discernible at × 250 and easily confirmed at × 25; 2 discrete granules resolved at × 100; 3 discrete granules resolved at × 25; 4 masses visible at × 10, or naked eye.

Immunohistochemical Analysis

We performed immunohistochemical analysis on 21 of the 80 itai-itai disease cases and 15 of the 70 control cases to investigate metallothionein expression. These cases were randomly selected from our list. After deparaffinization of specimens, proteinase K antigen retrieval (Histofine Nichirei, Tokyo, Japan) was performed for 5 min, followed by endogenous peroxidase blocking (5% H2O2 in methanol) for additional 5 min. After nonspecific binding blocking with 5% bovine serum albumin (Sigma-Aldrich, Tokyo, Japan), incubation with the prediluted primary antibody was carried out overnight at 4 °C, using mouse monoclonal anti-metallothionein antibody (IgG1, 1:300, clone UC1MT; Abcam, Cambridge, UK). The immunoreaction was visualized with diaminobenzidine–chromogen/EnVison Polymer–horseradish peroxidase (K4001; Dako, Glostrup, Denmark and SK4100; Vector Labs, Burlingame, CA, USA). Mild counterstaining was performed with hematoxylin. Staining intensity was scored on a four-point scale (0, 1+, 2+, 3+): 0, no positive staining; 1+, mild cytoplasmic staining; 2+, moderate-to-severe cytoplasmic staining; and 3+, moderate-to-severe cytoplasmic staining with nuclear staining. Scoring was performed by two independent pathologists (HB and KT), and the average score was adopted.

Statistical Analyses

Statistical analyses were performed using SPSS for Windows version 15.0 software (SPSS, Chicago, IL, USA). Cd concentration was expressed as mean±s.e.m. and analyzed by Student’s t-test. Comparison of pathological findings was analyzed by Pearson’s χ2-test. To compare scores obtained from immunohistochemical analysis, Mann–Whitney U-test was performed. Differences were considered significant at P-values <0.05.

Results

Cd Concentration in Organs

Cd concentration in organs is shown in Figure 1. Cd accumulated at a significantly higher concentration in the liver in the itai-itai disease group than that in the liver in the control group. Figure 1 also shows that in the itai-itai group, the liver had the highest concentration of Cd of organs tested, whereas in the control group, renal cortex had the highest levels, and more Cd than the liver in the disease group.

Figure 1
figure1

Average cadmium (Cd) concentration in selected organs. Significant differences were observed between the itai-itai disease and control groups for all organs examined (P<0.01).

Pathological Features

The results of pathological analysis are shown in Table 3. In the itai-itai disease group, fibrosis and hemosiderosis were observed at a significantly higher rate compared with the control group (P=0.0022 and 0.0006, respectively).

Table 3 Pathological findings observed in liver specimens of 80 itai-itai disease cases and 70 control cases

Of 19 cases with fibrosis, periportal fibrosis was observed in 9 (47%) , perisinusoidal and portal/periportal fibrosis in 5 (26%), and bridging fibrosis in 5 (26%) cases. Most fibrosis was observed around the portal region, with slender fibrotic extensions and a stellate pattern. Perivenular and pericellular fibrosis was not observed (Figures 2a and b).

Figure 2
figure2

(a, b) In the liver of itai-itai disease cases, fibrosis was observed in a stellate pattern around the portal region; (a) H&E, × 200, (b) Azan, × 200. (c, d) Iron accumulation was mainly in hepatocytes with a massive pattern in itai-itai disease cases with hemosiderosis; (c) H&E, × 200, (d) Berlin blue, × 200. (e) Inflammation observed in itai-itai disease cases was mainly located in portal regions. The infiltrating cells were primarily lymphocytes; H&E, × 200. (f) Macrovesicular and microvesicular fatty changes were mixed in itai-itai disease cases with steatosis; H&E, × 200. (g) Metallothionein was expressed in the cytoplasm and nuclei of hepatocytes in the liver of itai-itai disease cases; metallothionein immunohistochemistry, × 400. (h) Metallothionein was weakly expressed only in the cytoplasm of hepatocytes in the liver of control cases; metallothionein immunohistochemistry, × 400.

Of 15 cases with hemosiderosis, 6 were graded 2 and 9 were graded 3 according to the modified Scheuer’s scoring system. Iron was primarily located in hepatocytes but was also in some Kupffer cells in most cases. It was accumulated in a pelicanalicular pattern in two cases, and in a massive pattern in all other cases (Figures 2c and d). In the liver of the itai-itai disease group, statistically higher Cd concentration was recorded in cases with fibrosis than in those without fibrosis (t(76)=2.105, P<0.05). In contrast, no significant difference was observed between cases with hemosiderosis and those without hemosiderosis (t(76)=1.411, P>0.05).

Inflammation observed in 10 cases was mainly located in portal regions. In 4 out of 10 cases, mononuclear aggregates in some portal tracts. In three cases, mononuclear aggregates in all portal tracts (Figure 2e). In three cases, including two cases with hepatitis, large and dense mononuclear aggregates in all portal tracts. The infiltrating cells were mainly lymphocytes, and plasma cells were also confirmed. Eosinophils were observed in several cases.

In six cases with steatosis, macrovesicular and microvesicular fatty changes were mixed (Figure 2f). It was located in a centrilobular pattern in four cases, and diffusely in two cases. Glycogenerated nuclei were observed in two cases with steatosis. Hepatocellular carcinoma and other tumors were not observed in the livers of the itai-itai disease group. Megamitochondria and biliary tract changes were not observed.

Metallothionein Expression

Metallothionein was expressed more strongly in the itai-itai disease group than that in the control group (P=0.017) (Figures 2g, h and ). Whereas metallothionein expression was observed only in the cytoplasm of the liver in the control group, it was observed in the cytoplasm and at times in the nucleus in 6 cases (29%) in the itai-itai disease group. Cases with nuclear metallothionein expression had significantly higher Cd concentration than those with only cytoplasmic metallothionein expression (P=0.0051) (Figure 4).

Figure 3
figure3

Immunohistochemistry scoring for metallothionein. The error bars indicate 95% confidence interval. A significant difference was observed between the itai-itai disease and control groups (P=0.017).

Figure 4
figure4

The comparison of cadmium (Cd) concentration between itai-itai disease cases with nuclear metallothionein expression and those without nuclear metallothionein expression. A significant difference was observed between two groups (P=0.0051).

Discussion

Considerable hepatic and renal Cd accumulation is known to occur,18 and toxicological studies in animals show that hepatic Cd levels are initially the highest, followed by an increase in renal Cd levels after long-term exposure.19, 20, 21 Whereas the results of Cd concentration in our control group are consistent with the above-mentioned data, Cd concentration in the itai-itai disease group showed marked hepatic Cd accumulation, following renal injury because of chronic Cd exposure.

In the liver of the itai-itai disease group, but not the control group, slender, stellate-shaped fibrotic lesions were observed as a characteristic change, and a significant difference was observed in Cd concentration between cases with fibrosis and those without fibrosis. Therefore, fibrosis is thought to reflect Cd-specific changes. Several studies have confirmed the fibrogenic effect of Cd.22, 23, 24 Carmen et al25 reported that the role of Cd in liver fibrosis was the production of oxidative stress in vivo. The fibrotic liver may be subjected to exposure by continuous oxidative stress induced by Cd. We could not however identify contributing or underlying conditions to the phenotype of itai-itai disease cases with fibrosis from the available information. One of the possible biases is drug history. We are now trying to collect more detailed clinical information from various medical institutions. In further study, we need to clarify the specific backgrounds of fibrosis in itai-itai disease.

Although hemosiderosis was also observed at a significantly higher rate in the itai-itai disease group than that in the control group, various studies have shown that hepatic iron concentration was reduced when Cd was orally ingested through drinking water or through the diet,26, 27, 28 contradicting our findings. Many itai-itai disease patients receive blood transfusion for renal anemia; therefore, we need to consider the impact. Unfortunately, detailed clinical records were unavailable for the patients in our study, and further investigation will be required to determine the significance of hemosiderosis.

Although fibrosis and hemosiderosis can occur in itai-itai disease, the changes observed in this study were less severe compared with the acute hepatotoxicity induced by Cd exposure reported in other studies.22, 29, 30 Our results indicate that increased metallothionein expression can inhibit Cd hepatotoxicity. Many studies using metallothionein transgenic animals have demonstrated that metallothionein has an important protective role against Cd hepatotoxicity. Liu et al31 reported that mice overexpressing metallothionein were protected against acute Cd lethality and hepatotoxicity. In contrast, repeated administration of Cd chloride to metallothionein-null mice caused nonspecific chronic inflammation in the liver parenchyma and portal tracts, and higher doses produced granulomatous inflammation and preneoplastic proliferative lesions.32 These studies support the premise that high metallothionein expression in the liver of itai-itai disease patients can reduce hepatic damage.

An interesting point is that metallothionein was expressed in hepatocyte nuclei of some itai-itai disease cases. Numerous studies, both in vivo and in vitro, showed that the adult animal and human liver has a very low nuclear metallothionein content,33, 34, 35 so metallothionein expression in nuclei is thought to be a finding related to itai-itai disease. Metallothionein does not have nuclear localization signals, so nuclear trafficking of metallothionein requires binding to cytosolic substances.36, 37 Although metallothionein binds to various heavy metals, it is reasonable to consider that metallothionein binds to Cd under Cd-rich condition. Thus, nuclear metallothionein is thought to reflect the distribution of Cd. This is strongly supported by the result that metallothionein expression in nuclei was observed in cases with high Cd concentration. Therefore, the result of immunohistochemistry suggests that Cd accumulates in hepatocyte nuclei in itai-itai disease.

This is the first study to focus on liver pathology in itai-itai disease. Although several studies using animal models have evaluated the chronic effects of Cd exposure, the exposure period in these models was much shorter than that in humans in everyday life; therefore, it is difficult to apply these results directly to the chronic effects of Cd in humans. Therefore, we believe the findings of this study can be beneficial because they represent direct evidence of chronic human hepatotoxicity due to Cd. Considering that Cd exposure is expected to rise globally,4 further studies focusing on itai-itai disease patients are urgently required.

In conclusion, chronic exposure to low Cd doses leads to not only high hepatic Cd accumulation, which can cause fibrosis, but also high metallothionein expression. Highly expressed metallothionein is thought to reduce the hepatotoxic effects of Cd.

References

  1. 1

    Satarug S, Garrett SH, Sens MA et al. Cadmium, environmental exposure, and health outcomes. Environ Health Perspect 2010;118:182–190.

    CAS  Article  Google Scholar 

  2. 2

    Klaassen CD, Liu J, Diwan BA . Metallothionein protection of cadmium toxicity. Toxicol Appl Pharmacol 2009;238:215–220.

    CAS  Article  Google Scholar 

  3. 3

    Jarup L, Akesson A . Current status of cadmium as an environmental health problem. Toxicol Appl Pharmacol 2009;238:201–208.

    Article  Google Scholar 

  4. 4

    Nawrot TS, Staessen JA, Roels HA et al. Cadmium exposure in the population: from health risks to strategies of prevention. Biometals 2010;23:769–782.

    CAS  Article  Google Scholar 

  5. 5

    Suwazono Y, Sand S, Vahter M et al. Benchmark dose for cadmium-induced osteoporosis in women. Toxicol Lett 2010;197:123–127.

    CAS  Article  Google Scholar 

  6. 6

    Inaba T, Kobayashi E, Suwazono Y et al. Estimation of cumulative cadmium intake causing itai-itai disease. Toxicol Lett 2005;159:192–201.

    CAS  Article  Google Scholar 

  7. 7

    Nogawa K, Kido T . Biological monitoring of cadmium exposure in itai-itai disease epidemiology. Int Arch Occup Environ Health 1993;65:S43–S46.

    CAS  Article  Google Scholar 

  8. 8

    Rikans LE, Yamano T . Mechanisms of cadmium-mediated acute hepatotoxicity. J Biochem Mol Toxicol 2000;14:110–117.

    CAS  Article  Google Scholar 

  9. 9

    Karadeniz A, Cemek M, Simsek N . The effects of Panax ginseng and Spirulina platensis on hepatotoxicity induced by cadmium in rats. Ecotoxicol Environ Saf 2009;72:231–235.

    CAS  Article  Google Scholar 

  10. 10

    Nemmiche S, Chabane-Sari D, Guiraud P . Role of alpha-tocopherol in cadmium-induced oxidative stress in Wistar rat’s blood, liver and brain. Chem Biol Interact 2007;170:221–230.

    CAS  Article  Google Scholar 

  11. 11

    Newairy AA, El-Sharaky AS, Badreldeen MM et al. The hepatoprotective effects of selenium against cadmium toxicity in rats. Toxicology 2007;242:23–30.

    CAS  Article  Google Scholar 

  12. 12

    Klaassen CD, Liu J . Metallothionein transgenic and knock-out mouse models in the study of cadmium toxicity. J Toxicol Sci 1998;23:97–102.

    CAS  Article  Google Scholar 

  13. 13

    Bobillier-Chaumont S, Maupoil V, Berthelot A . Metallothionein induction in the liver, kidney, heart and aorta of cadmium and isoproterenol treated rats. J Appl Toxicol 2006;26:47–55.

    CAS  Article  Google Scholar 

  14. 14

    Ministry of Health and Welfare. Opinion of the Welfare Ministry with regard to ‘itai-itai’ disease in Toyama prefecture In: Environmental Agency (eds) Control of environmental pollution by cadmium. Environmental Health Division, Planning and Coordination Bureau: Tokyo, 1972, pp 199.

  15. 15

    Kasuya M, Teranishi H, Aoshima K et al. Renal toxicology with special reference to cadmium In: Abudulla M, Dashti H, Sarkar B, AI-Sayer H, AI-Naqueeb N, (eds) Metabolism of mineral and trace elements in human disease. Smith-Gordon, London, 1989, pp 111–121.

    Google Scholar 

  16. 16

    Kuzuhara Y, Minami M, Fujita M et al. Heavy metals in autopsy samples. Kankyo Hoken Rep 1985;51:162–195.

    Google Scholar 

  17. 17

    Turlin B, Deugnier Y . Evaluation and interpretation of iron in the liver. Semin Diagn Pathol 1998;15:237–245.

    CAS  PubMed  Google Scholar 

  18. 18

    Nakamura Y, Ohba K, Suzuki K et al. Health effects of low-level cadmium intake and the role of metallothionein on cadmium transport from mother rats to fetus. J Toxicol Sci 2012;37:149–156.

    CAS  Article  Google Scholar 

  19. 19

    Gunn SA, Gould TC . Selective accumulation of Cd115 by cortex of rat kidney. Proc Soc Exp Biol Med 1957;96:820–823.

    CAS  Article  Google Scholar 

  20. 20

    Nordberg GF . Historical perspectives on cadmium toxicology. Toxicol Appl Pharmacol 2009;238:192–200.

    CAS  Article  Google Scholar 

  21. 21

    Nordberg GF, Nishiyama K . Whole-body and hair retention of cadmium in mice including an autoradiographic study on organ distribution. Arch Environ Health 1972;24:209–214.

    CAS  Article  Google Scholar 

  22. 22

    Dudley RE, Svoboda DJ, Klaassen CD . Time course of cadmium-induced ultrastructural changes in rat liver. Toxicol Appl Pharmacol 1984;76:150–160.

    CAS  Article  Google Scholar 

  23. 23

    Kamiyama T, Miyakawa H, Li JP et al. Effects of one-year cadmium exposure on livers and kidneys and their relation to glutathione levels. Res Commun Mol Pathol Pharmacol 1995;88:177–186.

    CAS  PubMed  Google Scholar 

  24. 24

    Kaufmann I, Hopker WW, Deutsch-Diescher OG et al. Liver damage caused by chronic cadmium poisoning. Leber Magen Darm 1984;14:103–106.

    CAS  PubMed  Google Scholar 

  25. 25

    del Carmen EM, Souza V, Bucio L et al. Cadmium induces alpha(1)collagen (I) and metallothionein II gene and alters the antioxidant system in rat hepatic stellate cells. Toxicology 2002;170:63–73.

    CAS  Article  Google Scholar 

  26. 26

    Martelli A, Moulis JM . Zinc and cadmium specifically interfere with RNA-binding activity of human iron regulatory protein 1. J Inorg Biochem 2004;98:1413–1420.

    CAS  Article  Google Scholar 

  27. 27

    Noel L, Guerin T, Kolf-Clauw M . Subchronic dietary exposure of rats to cadmium alters the metabolism of metals essential to bone health. Food Chem Toxicol 2004;42:1203–1210.

    CAS  Article  Google Scholar 

  28. 28

    Oishi S, Nakagawa J, Ando M . Effects of cadmium administration on the endogenous metal balance in rats. Biol Trace Elem Res 2000;76:257–278.

    CAS  Article  Google Scholar 

  29. 29

    Chang YF, Wen JF, Cai JF et al. An investigation and pathological analysis of two fatal cases of cadmium poisoning. Forensic Sci Int 2012;220:e5–e8.

    CAS  Article  Google Scholar 

  30. 30

    Dudley RE, Svoboda DJ, Klaassen C . Acute exposure to cadmium causes severe liver injury in rats. Toxicol Appl Pharmacol 1982;65:302–313.

    CAS  Article  Google Scholar 

  31. 31

    Liu Y, Liu J, Iszard MB et al. Transgenic mice that overexpress metallothionein-I are protected from cadmium lethality and hepatotoxicity. Toxicol Appl Pharmacol 1995;135:222–228.

    CAS  Article  Google Scholar 

  32. 32

    Habeebu SS, Liu J, Liu Y et al. Metallothionein-null mice are more sensitive than wild-type mice to liver injury induced by repeated exposure to cadmium. Toxicol Sci 2000;55:223–232.

    CAS  Article  Google Scholar 

  33. 33

    Cherian MG . The significance of the nuclear and cytoplasmic localization of metallothionein in human liver and tumor cells. Environ Health Perspect 1994;102:131–135.

    CAS  PubMed  PubMed Central  Google Scholar 

  34. 34

    Cherian MG, Apostolova MD . Nuclear localization of metallothionein during cell proliferation and differentiation. Cell Mol Biol 2000;46:347–356.

    CAS  PubMed  Google Scholar 

  35. 35

    Nishimura H, Nishimura N, Tohyama C . Immunohistochemical localization of metallothionein in developing rat tissues. J Histochem Cytochem 1989;37:715–722.

    CAS  Article  Google Scholar 

  36. 36

    Nagano T, Itoh N, Ebisutani C et al. The transport mechanism of metallothionein is different from that of classical NLS-bearing protein. J Cell Physiol 2000;185:440–446.

    CAS  Article  Google Scholar 

  37. 37

    Takahashi Y, Ogra Y, Suzuki KT . Nuclear trafficking of metallothionein requires oxidation of a cytosolic partner. J Cell Physiol 2005;202:563–569.

    CAS  Article  Google Scholar 

Download references

Acknowledgements

We are grateful to Tokimasa Kumada, Hideki Hatta, Takeshi Nishida, and Yukari Inoue for their technical and secretarial assistance. We also thank Dr Kazuhito Kawata, Dr Hajime Tanaka, and Dr Michiya Sugimori for their helpful comments and discussions. This project was supported in part by a research Grant from the Ministry of the Environment, Japan (H22-H24).

Author information

Affiliations

Authors

Corresponding author

Correspondence to Koichi Tsuneyama.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Baba, H., Tsuneyama, K., Yazaki, M. et al. The liver in itai-itai disease (chronic cadmium poisoning): pathological features and metallothionein expression. Mod Pathol 26, 1228–1234 (2013). https://doi.org/10.1038/modpathol.2013.62

Download citation

Keywords

  • cadmium (Cd)
  • hepatotoxicity
  • itai-itai disease
  • metallothionein

Further reading

Search

Quick links